Application of GCA neutralizing antibodies
By developing GCA-Nab monoclonal antibodies, blocking the biological activity of particulate calcium proteins, solving the treatment problems of obesity and metabolic inflammation, achieving significant improvements in obesity-related insulin resistance and metabolic inflammation, and providing new drugs for treating obesity .
Patent Information
- Application Number
- CN202211289754.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-10-20
AI Technical Summary
The prior art lacks effective drugs to quickly and accurately prevent and treat obesity, obesity-related metabolic inflammation and insulin resistance, and existing blood sugar and lipid-lowering drugs often bring adverse side effects.
A GCA-Nab monoclonal antibody was developed to reduce the expression of inflammatory cytokines and proinflammatory Th1 cells in adipose tissues by blocking the biological activity of granule calcium proteins, improving insulin sensitivity and glucose homeostasis.
Effectively block the promoting effect of GCA on adipose tissue inflammation and insulin resistance, significantly improve obesity-related insulin resistance and metabolic inflammation, delay the development of metabolic syndrome, and provide a basis for research on new drugs for the treatment of obesity and related diseases.
Smart Images

Figure CN115990250B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to the use of a GCA neutralizing antibody in the preparation of a drug for preventing and / or treating obesity, obesity-related diseases, obesity-related metabolic inflammation, and insulin resistance. Background Art
[0002] According to relevant standards, BMI≧25Kg / m 2 Defined as overweight, BMI ≥ 30 kg / m 2 Defined as obesity. Metabolic inflammation is the main feature of obesity, and the interaction between bone and adipose tissue maintains metabolic homeostasis. In obese subjects, chronic low-grade inflammation occurs in adipose tissue and can progress to systemic inflammation. In addition, obesity-induced inflammation is an important pathogenic mediator of many metabolic diseases, such as cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus (T2DM), hyperglycemia, hyperlipidemia, arthritis and myocarditis, stroke and cancer. At present, the clinical treatment of obesity and improvement of metabolic inflammation mainly focuses on a reasonable and balanced diet and increased exercise, and there is no effective drug for rapid and accurate symptomatic treatment.
[0003] Insulin resistance is closely related to the development of obesity. Currently, the main strategies to improve insulin sensitivity and improve insulin resistance are diet control, moderate exercise, hypoglycemic and lipid-lowering drugs, etc. However, most hypoglycemic and lipid-lowering drugs can cause adverse side effects such as severe gastrointestinal reactions, skin allergies, and lactic acidosis.
[0004] Grancalcin (GCA) is a member of the Penta-EF-hand (PEF) protein family, a group of calcium-binding proteins with five EF-hand motifs. GCA-Nab, or GCA neutralizing antibody, can block the biological activity of GCA. However, there has been no report on the use of GCA neutralizing antibodies for the preparation of treatments for obesity-related metabolic inflammation and insulin resistance. Summary of the invention
[0005] The technical problem solved by the present invention is to overcome the defects that there is no specific drug in the prior art for preventing and / or treating obesity, diseases related to obesity, metabolic inflammation related to obesity and insulin resistance, the treatment cycle by controlling diet and the like is long and the effect is not obvious, while the auxiliary treatment by lowering blood sugar, blood lipids and the like drugs will bring about adverse side effects such as lactic acidosis, and further provide a use of GCA-NAb in the preparation of drugs for preventing and / or treating obesity, diseases related to obesity, metabolic inflammation related to obesity and insulin resistance.
[0006] The technical problem solved by the present invention is achieved by adopting the following technical solutions:
[0007] Use of GCA-NAb in the preparation of drugs for preventing and / or treating obesity, obesity-related diseases, obesity-related metabolic inflammation and insulin resistance.
[0008] Preferably, the obesity-related diseases include at least one of type II diabetes, non-alcoholic fatty liver disease, atherosclerosis, hyperglycemia, hyperlipidemia and hypertension.
[0009] Furthermore, the drug includes GCA-Nab monoclonal antibody or a hybridoma cell line secreting GCA-Nab monoclonal antibody.
[0010] Furthermore, the GCA-Nab monoclonal antibody is secreted by a hybridoma cell line with a deposit number of CCTCC NO: C2021182.
[0011] Furthermore, the gene sequence of GCA is shown in SEQ ID No.1.
[0012] Furthermore, the protein sequence of GCA is shown in SEQ ID No.2.
[0013] Furthermore, the drug reduces the expression levels of inflammatory cytokine genes in adipose tissue eWAT and pro-inflammatory Th1 marker genes in SVF.
[0014] Further, the drug increases insulin-induced AKT phosphorylation.
[0015] Beneficial effects: The present invention unexpectedly discovered that GCA neutralizing antibodies can effectively block the promoting effects of GCA on adipose tissue inflammation and insulin resistance, thereby significantly improving obesity-related insulin resistance and metabolic inflammation, and delaying the development of metabolic syndrome, thereby providing a research basis and theoretical basis for the development of drugs for preventing and / or treating obesity, obesity-related diseases, obesity-related metabolic inflammation and insulin resistance.
[0016] Specific:
[0017] GCA neutralizing antibodies can antagonize the proinflammatory effect of GCA on adipose tissue eWAT, improve obesity-related metabolic inflammation, and reduce the expression levels of inflammatory cytokine genes in eWAT and proinflammatory Th1 marker genes in SVF of obese mice.
[0018] GCA neutralizing antibodies can reduce the number of pro-inflammatory Th1 cells in SVF.
[0019] GCA neutralizing antibodies can improve glucose homeostasis and insulin sensitivity and increase insulin-induced AKT phosphorylation.
[0020] Biomaterial deposit information:
[0021] The hybridoma cell line of the present invention was deposited in the China Center for Type Culture Collection (CCTCC) on August 3, 2021, with the deposit address being Wuhan University, Luojia Mountain, Wuchang, Wuhan City, Hubei Province, China, Postal Code 430072, the deposit number being CCTCC NO: C2021182, and the culture name being hybridoma cell line GCA-NAB4. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 It is a screened GCA-Nab monoclonal antibody.
[0023] Figure 2 Schematic diagram of qPCR results of the effect of GCA-Nab on the gene expression of inflammatory factors in mouse eWAT (n=6).
[0024] Figure 3 Schematic diagram of the qPCR results of GCA-Nab on Th1 gene expression in SVF (n=6).
[0025] Figure 4-a Figure 1 is a statistical analysis of the effect of GCA-Nab on the number of CD4+TBET+Th1 cells in SVF cells using flow cytometry.
[0026] Figure 4-b Schematic diagram of the effect of GCA-Nab on the number of CD4+TBET+Th1 cells in SVF (II).
[0027] Figure 5 Schematic diagram of staining for F4 / 80 macrophage immunohistochemistry experiment, arrows indicate macrophages.
[0028] Figure 6a Schematic diagram of the effect of GCA-Nab on fasting blood glucose.
[0029] Figure 6b Schematic diagram of the effect of GCA-Nab on fasting insulin levels.
[0030] Figure 6c Schematic diagram of the effect of GCA-Nab on HOMA-IR index.
[0031] Figure 7a This is a graph showing the blood sugar changes during the ipGTT test.
[0032] Figure 7b This is a statistical analysis chart of the area under the ipGTT experiment curve.
[0033] Figure 7c This is a diagram of blood sugar changes in the ipITT experiment.
[0034] Figure 7dThis is a statistical analysis chart of the area under the ipITT experiment curve.
[0035] Figure 8 Schematic diagram of the results of immunoblot analysis of insulin-stimulated AKT phosphorylation in eWAT.
[0036] Figure 9a Schematic diagram of the statistical results of weight gain in mice after intravenous injection of GCA-NAb.
[0037] Figure 9b Schematic diagram of the weights of the liver, eWAT, iWAT and BAT collected after intravenous injection of GCA-NAb.
[0038] Fig.9c Schematic diagram of the results of daily food intake recording after intravenous injection of GCA-NAb. DETAILED DESCRIPTION
[0039] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further described below in conjunction with specific embodiments.
[0040] (A) Preparation of GCA neutralizing antibodies.
[0041] S1. Immunogen preparation and animal immunization
[0042] (1) Amplifying the target gene sequence as shown in SEQ ID No. 1 by PCR, inserting the target gene into the corresponding expression vector; sequencing to obtain a plasmid containing the correct sequence; and amplifying the plasmid to produce and deliver downstream expression.
[0043] (2) Extract bacmid DNA from E coli cells containing recombinant bacmids, infect insect cells to obtain P1 recombinant baculovirus. The P1 virus is then transferred into sf9 insect cells for further amplification to obtain high-titer P2 recombinant virus.
[0044] (3) The high-titer P2 recombinant virus was used to infect high-five insect cells in the logarithmic growth phase at a certain multiplicity of infection (MOI). The infected cells were cultured at 27 degrees Celsius for 2-3 days to express the target protein.
[0045] (4) Use an equilibrium buffer to equilibrate the chromatography column. After adding the fermentation broth supernatant or cell lysis supernatant after centrifugation filtration, rinse with the equilibrium buffer to remove some impurities, and then use a buffer containing different eluent (NaCl or imidazole) concentrations to elute the target protein. After collecting the eluted fractions, desalt the protein into a storage buffer. For insoluble proteins, denaturants such as urea may be added during cell lysis to dissolve the target protein and then purify it using a chromatography column. The eluted fraction containing the target protein is eluted from the chromatography column using a step-by-step dialysis method to remove the denaturant and renature the protein, and finally the renatured protein is desalted into a storage buffer.
[0046] (5) The obtained protein sample is subjected to purity detection and quantification by methods such as SDS-PAGE and UV OD 280. The desired immunogen GCA is thus produced, and its protein sequence is shown in SEQ ID No. 1.
[0047] (6) Immunize 5 Balb / c mice (each weighing about 16-20 g) at a dose of 50 μg / mouse (based on the mixture of "immunogen + adjuvant"). Mix the immunogen with an equal volume of adjuvant (complete / incomplete Freund's adjuvant, purchased from Sigma (Cat. No. F5881) and BD (Cat. No. 263910) respectively) and inject subcutaneously at multiple points in the abdomen. The second immunization is performed 2 weeks apart, and the third immunization is performed 3 weeks apart. After the three immunizations, blood is collected to determine the serum titer. Mice are selected for booster immunization, and the spleen of the mice is collected 3 days after the booster immunization for hybridoma fusion.
[0048] The following is the GCA gene and protein sequence
[0049] GCA gene sequence (SEQ ID No.1):
[0050] ATGCATCATCACCATCACCACCACCATCACCATCTGGAAGTCCTGTTTCAGGGACCCATGGCCTACCCGGGATACGGAGGAGGGTTTGGAAATTTTAGCATTCAGGTGCCAGGAATGCAGATGGGACAGCCAGTGCCAGAAACAGGCCCAGCTATACTCCTCGATGGATACTCTGGGCCAGCATATTCAGACACTTATTCCTCAGCTGGTGACTCCGTGTATACTTACTTCAGTGCTGTTGCTGGACAGGATGGTGAAGTGGATGCTGAAGAACTTCAGAGATGTTTGACACAGTCTGGAATTAATGGAACTTACTCTCCCTTCAGTTTGGAAACCTGCAGAATTATGATTGCCATGTTGGATAGAGATCACACAGGAAAAATGGGATTTAATGCATTCAAAGAGCTATGGGCAGCTCTTAATGCCTGGAAGGAAAACTTCATGACTGTTGATCAAGATGGAAGTGGCACAGTAGAACATCATGAGTTGCGTCAAGCCATTGGTCTTATGGGTTATAGGTTGAGTCCTCAAACATTAACTACTATTGTTAAACGTTATAGCAAGAATGGCAGAATTTTCTTTGATGATTATGTTGCTTGCTGTGTGAAGCTTCGAGCATTGACAGATTTCTTTAGGAAAAGAGACCACTTGCAACAAGGGTCTGCGAATTTCATATATGACGATTTTTTGCAGGGCACTATGGCAATTTAA。
[0051] GCA protein sequence (SEQ ID No.2):
[0052] MHHHHHHHHHHLEVLFQGPMAYPGYGGGFGNFSIQVPGMQMGQPVPE TGPAILLDGYSGPAYSDTYSSAGDSVYTYFSAVAGQDGEVDAEELQRCLT QSGINGTYSPFSLETCRIMIAMLDRDHTGKMGFNAFKELWAALNAWKEN FMTVDQDGSGTVEHHELRQAIGLMGYRLSPQTLTTIVKRYSKNGRIFFDD YVACCVKLRALTDFRKRDHLQQGSANFIYDDFLQGTMAI.
[0053] The basic physical and chemical properties of GCA protein are as follows: length 236 molecular weight (KDa) 26.4 isoelectric point 5.91 instability index 33.07 grand average of hydropathicity (GRAVY) -0.33.
[0054] S2. Blood collection and titer testing
[0055] One week after the last immunization, 50-60 μL of blood was collected from the mouse orbital venous plexus, and after standing at 4°C overnight, the upper serum was separated by centrifugation for testing;
[0056] An appropriate amount of detection protein was diluted to 5 μg / mL with coating buffer, and then 100 μL was added to each well of a 96-well plate with a single-channel pipette. The plate was gently tapped to mix the sample, and sealed with plastic wrap, and coated overnight at 4°C; the plate was washed once with a washing solution at 200 μL / well, and the ELISA plate was buckled dry; the ELISA plate was blocked with a blocking solution at 300 μL / well and blocked at room temperature for 1 hour; the plate was washed twice with a washing solution at 400 μL / well, and the sample was added (the gradient diluted sample and sample diluent were added at 100 μL / well), and the detection antibody was added at the same time, and added to the 96-well plate at 100 μL / well, and allowed to act at room temperature for 2 hours; the plate was washed 5 times with a washing solution at 400 μL / well, and the color developing solution was added at 200 μL / well and left at room temperature for 12 minutes; the reaction was terminated by adding a stop solution at 50 μL / well; and the detection was performed with an ELISA instrument: the measurement wavelength was 450 nm.
[0057] S3, fusion and screening
[0058] All spleen cells of immunized mice were taken and mixed with mouse myeloma cells at a ratio of 1:1. The cells were fused by electrofusion to obtain hybridoma cells. Antigen protein was used for coating, and the cell supernatant was determined by ELISA. The positive wells were selected for cloning by limiting dilution until a hybridoma cell line that stably secreted monoclonal antibodies was obtained. After screening, a total of 4 hybridoma cell lines were obtained, and their supernatants were all combined with the immunogen, that is, the monoclonal antibody GCA-Nab was successfully prepared (see Figure 1 ), and then the hybridoma cells with clone number MM04H were selected for antibody preparation (the deposit number is CCTCC NO: C2021182).
[0059] S4. Hybridoma small-scale culture
[0060] Transfer 1 mL of hybridoma cells into a 100 mL culture flask, add a certain amount of culture medium regularly for cell proliferation, and culture for 10 to 12 days.
[0061] S5. Purification
[0062] The Protein A affinity chromatography column was rinsed with ultrapure water and then equilibrated with an equilibrium buffer; the treated hybridoma cell supernatant was loaded onto the affinity chromatography column, and after loading, it was rinsed with an equilibrium buffer. The elution was performed with an elution buffer, and the elution peak was collected, neutralized with a Tris buffer, and desalted to PBS7.4 to obtain GCA-Nab.
[0063] (ii) GCA-NAb reduces obesity-related inflammation and improves insulin resistance tests by antagonizing GCA.
[0064] Eight-week-old mice were fed a high-fat diet for 12 weeks to induce a DIO mouse model (HFD-induced obesity). They were randomly divided into a control group and an experimental group. The control group was then injected with PBS through the tail vein, and the experimental group was injected with GCA-NAb (1 mg / kg) through the tail vein twice a week for 2 months. The body weight and food intake were recorded. After 2 months, ipGTT and ipITT experiments were performed, and fasting blood glucose and insulin levels were recorded to calculate the HOMA-IR index. The mice in each group were then killed, and the weights of the liver, eWAT, iWAT, and BAT were weighed, and all visceral fat was retained. One part was fixed with formaldehyde and dehydrated with alcohol gradients, embedded in paraffin, and sliced for immunohistochemical staining. One part was used to extract SVF cells for flow analysis, and the remaining part was directly extracted for protein and RNA, and protein and cDNA samples were prepared for Western Blot analysis and qPCR analysis.
[0065] (III) Analysis of experimental results. (Each value is expressed as the mean ± SD of three tests. *, marked as P < 0.05 compared with the control group cells treated with PBS, **, marked as P < 0.01 compared with the control group cells treated with PBS)
[0066] Table 1 Experimental results of the effect of GCA-Nab on the gene expression of inflammatory factors in mouse eWAT
[0067]
[0068]
[0069] As shown in Table 1 and Figure 2 As shown, compared with the PBS-treated control group, the gene expression of inflammatory factors in eWAT of mice injected with GCA-NAb via tail vein was significantly decreased, indicating that GCA-Nab treatment can reduce visceral adipose tissue inflammation.
[0070] Table 2 Experimental results of the effect of GCA-Nab on Th1 gene expression in SVF
[0071] Group Tbx21 relative expression level Ifng relative expression level PBS 1.085±0.124 1.083±0.105 GCA-Nab 0.798±0.072** 0.710±0.061**
[0072] As shown in Table 2 and Figure 3 As shown, the expression of Th1 genes in SVF of mice injected with GCA-NAb via tail vein was significantly decreased compared with that in the control group treated with PBS, indicating that GCA-Nab treatment can reduce the expression of pro-inflammatory Th1 cell mRNA.
[0073] Table 3 Experimental results of the effect of GCA-Nab on the number of CD4+TBET+Th1 cells in SVF
[0074] Group CD4+TBET+ cell ratio / % PBS 9.950±1.372 GCA-Nab 6.130±1.241*
[0075] As shown in Table 3 and Figure 4-a , Figure 4-b It can be seen that compared with the PBS-treated control group, the number of CD4+TBET+Th1 cells in the SVF cells of the experimental group injected with GCA-NAb via the tail vein of mice decreased, indicating that GCA-Nab treatment can reduce the production of pro-inflammatory Th1 cells.
[0076] Table 4 Experimental results of the effect of GCA-Nab on the number of F4 / 80 macrophages in ewat tissue sections
[0077] Group <![CDATA[Number of F4 / 80+ cells / mm 2 > PBS 6.55±0.241 GCA-Nab 2.13±0.256**
[0078] As shown in Table 4 and Figure 5 As shown, the number of F4 / 80 macrophages in the ewat tissue sections after GCA-NAb injection into the tail vein of the experimental group decreased compared with the PBS-treated control group.
[0079] Table 5 Experimental results of the effect of GCA-Nab on fasting blood glucose, fasting insulin levels and HOMA-IR index
[0080]
[0081]
[0082] From Table 5 and Figure 6a , Figure 6b , Figure 6c As shown, compared with the PBS-treated control group, the fasting blood glucose and fasting insulin levels and HOMA-IR index of the experimental group injected with GCA-NAb by tail vein were significantly decreased, indicating that GCA-Nab treatment can improve the blood glucose and insulin levels of obese mice.
[0083] Table 6 ipGTT test results
[0084]
[0085] Table 7 ipGTT area under the curve results
[0086] Group GTT-AUC PBS 2430.167±138.180 GCA-Nab 761.783±55.007**
[0087] Table 8 ipITT test results
[0088]
[0089] Table 9 ipITT area under the curve results
[0090]
[0091]
[0092] From Table 6-9 and Figure 7a , 7b As shown in Figures 7c and 7d, compared with the control group treated with PBS, the ipGTT and ipITT experiments of the experimental group injected with GCA-NAb by tail vein showed decreased blood glucose and increased insulin sensitivity, indicating that GCA-Nab treatment can improve insulin resistance in obese mice.
[0093] Table 10 Experimental results of GCA-Nab on insulin-stimulated AKT phosphorylation in eWAT
[0094] Group WB quantification (gray value) PBS 1.087±0.105 GCA-Nab 0.657±0.056**
[0095] From Table 10 and Figure 8 It can be seen that the immunoblot grayscale value of insulin-stimulated AKT phosphorylation in eWAT decreased in the experimental group compared with the PBS-treated control group after GCA-NAb was injected into the rat tail vein.
[0096] Table 11 Experimental results of the effect of GCA-Nab on body weight
[0097] Group PBS GCA-Nab Weight (g) 47.17±1.39 47.08±1.44
[0098] Table 12 Experimental results of the effect of GCA-Nab on the mass of white fat and brown fat
[0099] Group Liver weight (g) iWAT weight (g) eWAT weight (g) BAT weight (g) PBS 1.696±0.045 1.163±0.206 2.163±0.306 0.356±0.067 GCA-Nab 1.619±0.057* 1.231±0.303 2.043±0.332 0.391±0.034
[0100] Table 13 Experimental results of the effect of GCA-Nab on food intake
[0101] Group Daily food intake (g) PBS 3.267±0.667 GCA-Nab 3.267±0.593
[0102] From Tables 11 to 13 and Figure 9a , 9b , 9c, it can be seen that compared with the PBS-treated control group, the mice injected with GCA-NAb by tail vein had no significant differences in body weight, white fat, brown fat mass or food intake.
[0103] In summary, GCA-Nab can effectively block the promoting effect of GCA on adipose tissue inflammation and insulin resistance, thereby significantly improving obesity-related insulin resistance and metabolic inflammation, and delaying the development of metabolic syndrome.
[0104] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. Use of GCA-Nab monoclonal antibody in the preparation of drugs for preventing and / or treating obesity and insulin resistance; the GCA-Nab monoclonal antibody is secreted by a hybridoma cell line with a deposit number of CCTCC NO: C2021182.
2. The use according to claim 1, characterized in that: The gene sequence of GCA is shown in SEQ ID No.
1.
3. The use according to claim 1, characterized in that: The protein sequence of GCA is shown in SEQ ID No.
2.
4. The use according to claim 1, characterized in that: The drug reduces the expression levels of inflammatory cytokine genes in adipose tissue eWAT and pro-inflammatory Th1 marker genes in SVF.
5. The use according to claim 1, characterized in that: The drug increases insulin-induced AKT phosphorylation.
